ECSP14015609A - Inhibidores de pde9 con estructura básica de imidazotriazinona - Google Patents
Inhibidores de pde9 con estructura básica de imidazotriazinonaInfo
- Publication number
- ECSP14015609A ECSP14015609A ECIEPI201415609A ECPI201415609A ECSP14015609A EC SP14015609 A ECSP14015609 A EC SP14015609A EC IEPI201415609 A ECIEPI201415609 A EC IEPI201415609A EC PI201415609 A ECPI201415609 A EC PI201415609A EC SP14015609 A ECSP14015609 A EC SP14015609A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- formula
- effective amount
- imidazotriazinone
- basic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos, que son inhibidores de la enzima PDE9. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para preparar compuestos de fórmula (I). La presente invención proporciona además un método para tratar un sujeto que padece un trastorno neurodegenerativo que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I). La presente invención proporciona además un compuesto de fórmula (I) para su uso en un método para tratar un sujeto que padece un trastorno psiquiátrico que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012070718 | 2012-01-26 | ||
| CN2012080208 | 2012-08-16 | ||
| PCT/EP2013/051451 WO2013110768A1 (en) | 2012-01-26 | 2013-01-25 | Pde9 inhibitors with imidazo triazinone backbone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14015609A true ECSP14015609A (es) | 2015-12-31 |
Family
ID=47603775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201415609A ECSP14015609A (es) | 2012-01-26 | 2014-08-25 | Inhibidores de pde9 con estructura básica de imidazotriazinona |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9434733B2 (es) |
| EP (2) | EP2807163B1 (es) |
| CN (2) | CN107082783B (es) |
| AP (1) | AP2014007820A0 (es) |
| AU (2) | AU2013213603B2 (es) |
| BR (1) | BR112014018199A8 (es) |
| CO (1) | CO7020913A2 (es) |
| CR (1) | CR20140361A (es) |
| DO (1) | DOP2014000175A (es) |
| EC (1) | ECSP14015609A (es) |
| HK (1) | HK1199879A1 (es) |
| MX (1) | MX351582B (es) |
| PH (1) | PH12014501695B1 (es) |
| SG (1) | SG11201403909RA (es) |
| WO (1) | WO2013110768A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR083058A1 (es) | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | Compuestos de estructura de imidazotriazinona |
| EP2624903B1 (en) | 2010-10-08 | 2018-05-16 | Fisher & Paykel Healthcare Limited | Breathing assistance apparatus |
| EP2906562B1 (en) | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| CN107082783B (zh) * | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
| HK1206726A1 (en) | 2012-03-19 | 2016-01-15 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| WO2017000276A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| ES2971969T3 (es) * | 2015-07-07 | 2024-06-10 | H Lundbeck As | Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| CN114903900A (zh) | 2016-07-06 | 2022-08-16 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| AU2017350477A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| JP6990702B2 (ja) * | 2016-11-18 | 2022-01-13 | インテグレーティブ リサーチ ラボラトリーズ スウェーデン アーベー | 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 |
| CA3051976A1 (en) * | 2017-02-23 | 2018-08-30 | Boehringer Ingelheim International Gmbh | New medical use of compound iii |
| CA3064004A1 (en) | 2017-05-26 | 2018-11-29 | Imara Inc. | Methods of making and using pde9 inhibitors |
| CN110003213B (zh) * | 2018-01-04 | 2021-10-08 | 南京农业大学 | 苯并咪唑并三嗪酮类化合物、制备方法及应用 |
| EP3697423A4 (en) | 2018-01-05 | 2021-08-11 | Dicerna Pharmaceuticals, Inc. | REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY |
| MA52792A (fr) | 2018-05-25 | 2021-04-14 | Imara Inc | Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one |
| KR20250108770A (ko) | 2018-08-31 | 2025-07-15 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| TW202108585A (zh) * | 2019-05-07 | 2021-03-01 | 美商伊馬拉公司 | 用於治療地中海型貧血之pde9抑制劑 |
| CN113072556B (zh) * | 2021-03-30 | 2022-02-01 | 牡丹江医学院 | 一种用于治疗胶质瘤的药物及其制备方法 |
| EP4618980A1 (en) * | 2022-11-15 | 2025-09-24 | Freedom Biosciences, Inc. | Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309332C (en) | 1997-11-12 | 2002-12-03 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| BR0007613A (pt) | 1999-01-20 | 2001-10-30 | Dresden Arzneimittel | Aplicação de imidazo[1,5-a]-pirido[3,2-e]-pirazinonascomo medicamento |
| KR20040053210A (ko) * | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
| US6684626B1 (en) | 2002-07-30 | 2004-02-03 | General Electric Company | Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2005041972A1 (en) | 2003-10-31 | 2005-05-12 | Pfizer Products Inc. | Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
| AR053090A1 (es) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| JP5578786B2 (ja) | 2006-12-13 | 2014-08-27 | あすか製薬株式会社 | キノキサリン誘導体 |
| SI2152712T1 (sl) | 2007-05-11 | 2012-03-30 | Pfizer | Amino heterociklične spojine |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| EA201070725A1 (ru) | 2007-12-10 | 2011-02-28 | Глэксо Груп Лимитед | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| EP2456311A4 (en) | 2009-07-24 | 2013-01-23 | Concert Pharmaceuticals Inc | SUBSTITUTED IMIDASOTRIAZINES |
| WO2011028820A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| AR083058A1 (es) | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | Compuestos de estructura de imidazotriazinona |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| CN107082783B (zh) * | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
-
2013
- 2013-01-25 CN CN201710176546.6A patent/CN107082783B/zh active Active
- 2013-01-25 MX MX2014008912A patent/MX351582B/es active IP Right Grant
- 2013-01-25 AP AP2014007820A patent/AP2014007820A0/xx unknown
- 2013-01-25 CN CN201380006255.2A patent/CN104093720B/zh active Active
- 2013-01-25 BR BR112014018199A patent/BR112014018199A8/pt active Search and Examination
- 2013-01-25 EP EP13701270.4A patent/EP2807163B1/en active Active
- 2013-01-25 SG SG11201403909RA patent/SG11201403909RA/en unknown
- 2013-01-25 HK HK15100346.4A patent/HK1199879A1/xx unknown
- 2013-01-25 US US14/374,278 patent/US9434733B2/en active Active
- 2013-01-25 EP EP17152165.1A patent/EP3178820B1/en active Active
- 2013-01-25 WO PCT/EP2013/051451 patent/WO2013110768A1/en not_active Ceased
- 2013-01-25 AU AU2013213603A patent/AU2013213603B2/en active Active
-
2014
- 2014-07-24 CO CO14161415A patent/CO7020913A2/es unknown
- 2014-07-24 CR CR20140361A patent/CR20140361A/es unknown
- 2014-07-25 PH PH12014501695A patent/PH12014501695B1/en unknown
- 2014-07-25 DO DO2014000175A patent/DOP2014000175A/es unknown
- 2014-08-25 EC ECIEPI201415609A patent/ECSP14015609A/es unknown
-
2016
- 2016-04-04 US US15/089,819 patent/US9533992B2/en active Active
- 2016-11-22 US US15/358,168 patent/US9850249B2/en active Active - Reinstated
-
2017
- 2017-02-09 AU AU2017200886A patent/AU2017200886B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107082783B (zh) | 2019-03-22 |
| PH12014501695B1 (en) | 2019-06-03 |
| DOP2014000175A (es) | 2014-08-31 |
| US20160213674A1 (en) | 2016-07-28 |
| CN104093720A (zh) | 2014-10-08 |
| CN107082783A (zh) | 2017-08-22 |
| SG11201403909RA (en) | 2014-10-30 |
| PH12014501695A1 (en) | 2014-10-20 |
| CR20140361A (es) | 2014-11-11 |
| US9434733B2 (en) | 2016-09-06 |
| EP2807163B1 (en) | 2017-03-22 |
| US9533992B2 (en) | 2017-01-03 |
| EP3178820A1 (en) | 2017-06-14 |
| HK1199879A1 (en) | 2015-07-24 |
| AU2017200886B2 (en) | 2018-01-18 |
| AP2014007820A0 (en) | 2014-07-31 |
| US20150045348A1 (en) | 2015-02-12 |
| AU2013213603B2 (en) | 2017-02-02 |
| AU2017200886A1 (en) | 2017-03-02 |
| BR112014018199A8 (pt) | 2021-03-02 |
| US20170081333A1 (en) | 2017-03-23 |
| WO2013110768A1 (en) | 2013-08-01 |
| MX2014008912A (es) | 2014-08-26 |
| EP3178820B1 (en) | 2017-12-20 |
| EP2807163A1 (en) | 2014-12-03 |
| US9850249B2 (en) | 2017-12-26 |
| MX351582B (es) | 2017-10-20 |
| AU2013213603A1 (en) | 2014-07-24 |
| CO7020913A2 (es) | 2014-08-11 |
| CN104093720B (zh) | 2017-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14015609A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
| IN2015DN02829A (es) | ||
| ECSP13012698A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| CR20120319A (es) | Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a | |
| CO6321263A2 (es) | Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| DOP2012000168A (es) | Derivados de 2-arimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| MX2012006715A (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a. | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
| DOP2013000108A (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone |